Evidence map›Paper›PMID 41030936›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Validation of a Mitochondrial Polygenic Score for Parkinson's Disease.

Joshua Chin Ern Ooi, Yi Wen Tay, Ai Huey Tan, Chin-Hsien Lin, Kajsa Atterling Brolin, Björn-Hergen Laabs, Sebastian Sendel, Inke R König, Amke Caliebe, Carolin Gabbert and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Joshua Chin Ern OoiNeurology Unit, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia.
Yi Wen TayDepartment of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Ai Huey TanDivision of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Chin-Hsien LinDepartment of Neurology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
Kajsa Atterling BrolinTranslational Neurogenetics Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Björn-Hergen LaabsInstitute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany.
Sebastian SendelInstitute of Medical Informatics and Statistics, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.
Inke R KönigInstitute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany.
Amke CaliebeInstitute of Medical Informatics and Statistics, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.
Carolin GabbertInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Katherine M AndershCenter for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Lietsel JonesCenter for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Lara Mariah LangeInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Brian FiskeThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Carolyn SueNeuroscience Research Australia (NeuRA), NSW, Australia.
Christine KleinInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Joanne TrinhInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Theresa LüthInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mitochondrial dysfunction is a key player in Parkinson's disease (PD) pathogenesis. Mitochondrial polygenic scores (MGS) may be associated with PD but require validation across diverse populations. Objective: To validate the association between the MGS, PD status and age-at-onset (AAO) in idiopathic and Methods: We analyzed data from 17,129 PD patients and 13,872 healthy individuals across 10 ancestries within the Global Parkinson's Disease Genetic Program. We used regression models to assess the association between MGS, PD status and AAO. Results: The MGS was associated with iPD in Europeans (β=0.19, SE=0.02, p<2.0×10 Conclusions: The MGS is robustly associated with iPD status in Europeans and Ashkenazi Jews and with

Identifiers

PMID41030936
PMCPMC12478347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.